Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Earnings Results

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86, RTT News reports. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis.

Regeneron Pharmaceuticals Trading Up 6.2 %

Shares of REGN traded up $41.29 during mid-day trading on Tuesday, reaching $708.14. The company had a trading volume of 1,111,263 shares, compared to its average volume of 902,338. The firm has a fifty day simple moving average of $719.16 and a 200-day simple moving average of $918.90. The stock has a market cap of $77.82 billion, a price-to-earnings ratio of 17.53, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Analysts Set New Price Targets

Several brokerages have recently commented on REGN. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Bernstein Bank dropped their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday. Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $983.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.